

This newsletter summarises final decisions from HTA bodies around the world from May 2023.

These decisions have been categorised into one of four groups. You can click on the category you are interested in to jump to that section.

[Pharmacological Technologies](#)

[Non-pharmacological Technologies](#)

[Diagnostic Tests](#)

[Other Guidance](#)

Within each section the reports have been grouped according to clinical speciality. On the section contents page, there are shortcuts to each clinical speciality and specific report. All tiles are hyperlinked to the report file or to the HTA website.

Here we list a key for the decisions made by the HTA bodies for the reports listed in this newsletter.



Approved - This is where the reporting document states that the technology has been approved.



Not approved - This is where the reporting document states that the technology has not been approved.



Terminated - The report was terminated, additional details are provided under the icon.



Excluded - The report was excluded because it is covered by another HTA body in that country.



Unclear - This is where documentation cannot be translated or it is unclear on the reporting outcome.



Note - This entry includes a note from the report relating to the technology.




Evidence review - This is for reports that do not report a decision but summarises the evidence for the technology.

## Pharmacological Technologies



Cancer

- [Capmatinib - England](#)
- [Ciltacabtagene Autoleucel - Germany](#)
- [Ciltacabtagene Autoleucel - England](#)
- [Dabrafenib - Wales](#)
- [Darolutamide - Australia](#)
- [Dasatinib - Australia](#)
- [Epkoritamab - Finland](#)
- [Ibrutinib - Germany](#)
- [Ibrutinib with venetoclax - England](#)
- [Mosunetuzumab - England](#)
- [Olaparib - England](#)
- [Olaparib - England](#)
- [Pembrolizumab - Australia](#)
- [Pembrolizumab - England](#)
- [Ponatinib - Brazil](#)
- [Ripretinib - England](#)
- [Selpercatinib - France](#)
- [Sotorasib - Germany](#)
- [Tafasitamab - Scotland](#)
- [Tafasitamab - England](#)
- [Talazoparib - France](#)
- [Tebentafuspi - Finland](#)
- [Trastuzumab deruxtecan - France](#)
- [Trastuzumab deruxtecan - Germany](#)
- [Trastuzumab deruxtecan - Germany](#)
- [Trastuzumab deruxtecan - Finland](#)
- [Zanubritinib - France](#)




Cardiovascular

- [Benazepril - Brazil](#)
- [Benazepril/amlodipine - Brazil](#)
- [Chlorthalidone - Brazil](#)
- [Empagliflozin - Scotland](#)
- [Icosapent - Scotland](#)
- [Inclisiran - Australia](#)
- [Losartan- hydrochlorothiazide - Brazil](#)



Eye

- [Carmellose/glycerol/hyaluronic acid - Australia](#)
- [Dexamethasone - Brazil](#)
- [Hyaluronic acid - Australia](#)



Gastrointestinal

- [Risankizumab - England](#)

## Pharmacological Technologies




### Infection

- [Lenacapavir - Wales](#)
  - [Rezafungin - France](#)
- 



### Neurology

- [Daridorexant - Germany](#)
  - [Fenfluramine - Germany](#)
  - [Lasmiditan - Netherlands](#)
  - [Rimegepant - Scotland](#)
  - [Rimegepant - Scotland](#)
  - [Rimegepant - Wales](#)
- 




### Renal

- [Difelikefalin - England](#)
  - [Voclosporin - England](#)
- 



### Respiratory

- [Fluticasone - Australia](#)
- 



### Skin

- [Spesolimab - Germany](#)
- 



### Surgery

- [Chloroprocaine - Canada](#)

## Non-pharmacological Technologies



Cancer

- MRI-guided radiation therapy - Spain
- 




Eye

- Surgical device - Spain
- 



Mental Health

- Digital technology - England
  - Digital technology - England
- 



Musculoskeletal

- Brace compression - Norway
- 



Neurology

- Nerve stimulation - England

## Diagnostic Tests




Cancer

- [MRI fusion biopsy - England](#)
- 



Infection

- [PoC Test - England](#)
- 



Cardiovascular

- [Automated ankle BPI - England](#)
- [AQuAS - Spain](#)
- [CTCA - Germany](#)

## Other Guidance




### Blood

- [ABC - Korea](#)
  - [Liquid-based Cytology - Korea](#)
  - [Mitochondria EM - Korea](#)
  - [SNP marker analysis - Korea](#)
- 



### Cancer

- [Bevacizumab - Canada](#)
  - [Futibatinib - Austria](#)
  - [Carbon-ion radiotherapy - Korea](#)
  - [Glofitamab - Austria](#)
  - [Nutrition - USA](#)
  - [Pirtobrutinib - Austria](#)
- 



### Cardiovascular

- [AI screening ECG - Korea](#)
  - [Valve replacement - Korea](#)
- 



### Endocrine

- [QCT - Korea](#)
- 



### Eye

- [IRIS - Korea](#)
- 



### Genitourinary


- [Water cleansing - Korea](#)
- 



### Infection

- [COVID-19 RT-LAMP - Korea](#)
- [Mycobacterium avium complex test - Korea](#)
- [Non-TB Mycobacterium species test - Korea](#)

## Other Guidance



- [Extracorporeal shock wave therapy - Austria](#)
- [Plasma injection - Korea](#)
- [Prolotherapy - Korea](#)

### Musculoskeletal

---



- [Alternative Therapies - Canada](#)
- [Nerve stimulation - Austria](#)
- [Nerve blocks - Korea](#)

### Neurology


---



- [IV-Ig - Austria](#)
- [Management of PHD - USA](#)

### Pregnancy

---



- [Alternative Therapies - Canada](#)

### Skin

## Pharmacological Technologies



## Cancer



### Capmatinib

Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping

NICE TA884

- England
- 03 May 2023



\*no submission



### Ciltacabtagene Autoleucel

Ciltacabtagene autoleucel in multiple myeloma

IQWiG G23-04

- Germany
- 15 May 2023



\*orphan drug status



### Ciltacabtagene Autoleucel

Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma

NICE TA889

- England
- 17 May 2023



\*submission withdrawn



### Dabrafenib

Dabrafenib (Tafinlar®) in advanced BRAF V600 mutation-positive non-small-cell lung cancer

AWMSG 2509

- Wales
- 18 May 2023



\*covered by NICE TA898



## Pharmacological Technologies



## Cancer



Darolutamide

Darolutamide for the treatment of metastatic hormone-sensitive prostate cancer

PBAC

- Australia
- May 2023



\*under risk-sharing agreement



Dasatinib

Dasatinib and imatinib for maintenance therapy of Ph+ acute lymphoblastic leukaemia

PBAC

- Australia
- May 2023



\*for subsidised access



Epkoritamab

Epkoritamab for diffuse large B-cell lymphoma

FinCCHTA

- Finland
- May 2023



Ibrutinib

Ibrutinib for first-line therapy of chronic lymphocytic leukaemia, first line

IQWiG A23-04

- Germany
- 02 May 2023



## Pharmacological Technologies



## Cancer



**Ibrutinib with  
venetoclax**

Ibrutinib with  
venetoclax for untreated  
chronic lymphocytic  
leukaemia

*NICE TA891*

- England
- 31 May 2023



\*under commercial  
arrangement



**Mosunetuzumab**

Mosunetuzumab for  
relapsed or refractory  
follicular lymphoma

*NICE - TA892*

- England
- 31 May 2023



**Olaparib**

Olaparib for adjuvant  
treatment of BRCA  
mutation-positive HER2-  
negative high-risk early  
breast cancer after  
chemotherapy

*NICE TA886*

- England
- 10 May 2023



\*under commercial  
arrangement



**Olaparib**

Olaparib for previously  
treated BRCA mutation-  
positive hormone-  
relapsed metastatic  
prostate cancer

*NICE TA887*

- England
- 10 May 2023



\*under commercial  
arrangement

## Pharmacological Technologies



## Cancer



**Pembrolizumab**

- Australia
- May 2023

Pembrolizumab in patients with Stage IIIB, Stage IIIC or Stage IIID melanoma

PBAC



**Pembrolizumab**

- England
- 03 May 2023

Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer

NICE TA885



\*under managed access scheme



**Ponatinib**

- Brazil
- 03 May 2023

Ponatinib hydrochloride in adults with resistant/refractory chronic myeloid leukaemia

CONITEC



**Ripretinib**

- England
- 03 May 2023

Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments

NICE TA881



## Pharmacological Technologies



## Cancer



Selpercatinib

Selpercatinib monotherapy for 2nd line therapy in advanced medullary thyroid cancer (CMT) with a mutation in the RET gene

HAS AP195

- France
- 24 May 2023



Sotorasib

Sotorasib second-line for non-small-cell lung cancer

IQWiG A23-06

- Germany
- 02 May 2023



Tafasitamab

Tafasitamab with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma ineligible for autologous stem cell transplant

SMC 2522

- Scotland
- 09 May 2023



Tafasitamab

Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma

NICE TA883

- England
- 03 May 2023



## Pharmacological Technologies



## Cancer



Talazoparib

Talazoparib for prostate cancer

HAS AP183

- France
- 12 May 2023



Tebentafuspi

Tebentafuspi for Treatment of choroidal melanoma of the eye

FinCCHTA

- Finland
- May 2023



Trastuzumab deruxtecan

Trastuzumab deruxtecan for HER2 breast cancer

HAS AP196

- France
- 24 May 2023



Trastuzumab deruxtecan

Trastuzumab deruxtecan for breast carcinoma with or without visceral disease

IQWiG A23-07

- Germany
- 02 May 2023



## Pharmacological Technologies



## Cancer



**Trastuzumab  
deruxtecan**

- Germany
- 02 May 2023

Trastuzumab  
deruxtecan for 2nd/ 3rd-  
line therapy in gastric  
carcinoma

*IQWiG A23-08*



**Trastuzumab  
deruxtecan**

- Finland
- May 2023

Trastuzumab  
deruxtecan for  
metastatic HER2-  
positive  
adenocarcinoma of the  
stomach and  
oesophageal-gastric  
border, second line

*FinCCHTA*



**Zanubritinib**


- France
- 16 May 2023

Zanubrutinib for  
relapsed/refractory  
chronic lymphocytic  
leukaemia

*HAS AP186*



## Pharmacological Technologies



## Cardiovascular



**Benazepril**

Benazepril for adults with systemic arterial hypertension with inadequate control with monotherapy

CONITEC 818/2023

- Brazil
- 03 May 2023



**Benazepril/  
amlodipine**

Benazepril in amlodipine association for adults with systemic arterial hypertension with inadequate control with monotherapy

CONITEC 819/2023

- Brazil
- 03 May 2023



**Chlorthalidone**

Chlorthalidone for older adults with systemic arterial hypertension and inadequate control with monotherapy

CONITEC 820/2023

- Brazil
- 03 May 2023



**Empagliflozin**


Empagliflozin for symptomatic chronic heart failure with preserved ejection fraction

SMC 25231

- Scotland
- 09 May 2023



## Pharmacological Technologies



## Cardiovascular



### Icosapent

- Scotland
- 09 May 2023

Icosapent ethyl in adult statin-treated patients at high cardiovascular risk

SMC 2531



### Inclisiran

- Australia
- May 2023

Inclisiran in heterozygous familial hypercholesterolaemia and non-familial hypercholesterolaemia with atherosclerotic cardiovascular disease

PBAC



### Losartan-hydrochlorothiazide

- Brazil
- 03 May 2023

Fixed combination of losartan plus hydrochlorothiazide for adults with systemic arterial hypertension with inadequate blood pressure control

CONITEC 817/2023





## Pharmacological Technologies



**Carmellose/glycerol/  
hyaluronic acid**

- Australia
- May 2023

Carmellose/glycerol/  
hyaluronic acid in  
severe dry eye  
syndrome

PBAC



**Dexamethasone**

- Brazil
- 03 May 2023

Dexamethasone implant  
for the treatment of  
diabetic macular  
oedema as a therapeutic  
option to anti-VEGFs  
(ranibizumab and  
aflibercept)

CONITEC



**Hyaluronic acid**

- Australia
- May 2023


Hyaluronic acid with  
polyethylene glycol 400,  
propylene glycol, and  
hydroxypropyl guar  
multi-dose preservative-  
free eye drops in severe  
dry eye syndrome

PBAC




\*if cost matches cheapest  
ocular lubricant

## Pharmacological Technologies



### Gastrointestinal



### Infection



Risankizumab

Risankizumab for previously treated moderately to severely active Crohn's disease

NICE TA888

- England
- 17 May 2023



\*under commercial arrangement



Lenacapavir

Lenacapavir for multidrug-resistant HIV-1

AWMSG 4845

- Wales
- 16 May 2023



\*covered by NICE ID6196



Rezafungin

Rezafungin for adult patients ( $\geq 18$  years) with invasive candidiasis or candidemia whose venous approach is difficult

HAS AP148

- France
- 15 May 2023



## Pharmacological Technologies



## Neurology



Daridorexant

Daridorexant for chronic insomnia

*IQWiG A22-123*

- Germany
- 12 May 2023



Fenfluramine

Fenfluramine add-on therapy in Lennox-Gastaut syndrome

*IQWiG G23-03*

- Germany
- 15 May 2023



\*orphan drug status



Lasmiditan

Lasmiditan for migraine

*Zorginstituut Nederland*

- Netherlands
- 23 May 2023



Rimegepant

Rimegepant for acute treatment of refractory migraine with or without aura in adults

*SMC 2521*

- Scotland
- 09 May 2023



\*for restricted use

## Pharmacological Technologies



### Neurology



Rimegepant

- Scotland
- 09 May 2023

Rimegepant for the preventive treatment of episodic migraine in adults

SMC 2567



Rimegepant

- Wales
- 31 May 2023


Rimegepant for the preventive treatment of episodic migraine

AWMSG 5281



\*covered by NICE ID6275

## Pharmacological Technologies



### Renal



### Respiratory



Difelikefalin

- England
- 17 May 2023

Difelikefalin for treating pruritus in people having haemodialysis

NICE TA890



\*under commercial arrangement



Fluticasone

- Australia
- May 2023

Fluticasone propionate in asthma in patients aged 6 years and above

PBAC



\*with a price reduction



Voclosporin

- England
- 03 May 2023


Voclosporin with mycophenolate mofetil for treating lupus nephritis

NICE TA882



\*under commercial arrangement

## Pharmacological Technologies



### Skin



### Surgery



**Spesolimab**

Spesolimab in  
generalized pustular  
psoriasis

*IQWiG A23-05*

- Germany
- 02 May 2023



**Chloroprocaine**

Chloroprocaine for  
spinal or epidural  
anesthesia

*CADTH RC1482-000*

- Canada
- 19 May 2023



Improved efficacy, cost-  
effectiveness unclear

## Non-pharmacological Technologies



### Cancer



### Eye



#### MRI-guided radiation therapy

Safety, efficacy and efficiency of MRI-guided radiation therapy in prostate cancer

AETSA

- Spain
- May 2023



#### Surgical device

Effectiveness, safety and efficiency of subconjunctival drainage devices with AB-internal approach for primary open-angle glaucoma

IACS

- Spain
- 2023



XEN®45 implant may be most cost-effective

## Non-pharmacological Technologies




### Mental Health



Digital technology

- England
- 16 May 2023

 Digitally enabled therapies for adults with depression disorders

NICE HTE8




\*after DTAC approval



Digital technology

- England
- 16 May 2023

 Digitally enabled therapies for adults with anxiety disorders


NICE HTE9



\*after DTAC approval



## Non-pharmacological Technologies



### Musculoskeletal



### Neurology



#### Brace compression

Brace compression for treatment of pectus carinatum

*NIPH*

- Norway
- 15 May 2023



#### Nerve stimulation

Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries

*NICE IPG762*

- England
- 24 May 2023



\*under special arrangements

## Diagnostic Tests



### Cancer



### Infection



#### MRI fusion biopsy

MRI fusion biopsy systems for diagnosing prostate cancer

NICE DG53

- England
- 24 May 2023



#### PoC Test


Point-of-Care tests for urinary tract infections to improve antimicrobial prescribing: early value assessment

NICE HTE7

- England
- 04 May 2023



## Diagnostic Tests



## Cardiovascular



### Automated ankle BPI

- England
- 24 May 2023

Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers

NICE DG52



### CTCA

- Germany
- 31 May 2023

Computed Tomography Coronary Angiography for diagnosis in patients with suspected chronic coronary artery disease

IQWiG D22-01



### AQuAS


- Spain
- May 2023

Safety, efficacy and economic evaluation of the implementation of an abdominal aortic aneurysm screening program (AQuAS)



Additional cost €15.68 to €28.40 per screened patient

## Other Guidance




## Blood



ABC

- Korea
- 08 May 2023


ABC bleeding risk score 

NECA HTA-2023-25



Liquid-based  
Cytology

- Korea
- 08 May 2023


Liquid-based cytology system using centrifuge automation technology 

NECA HTA-2023-22



Mitochondria EM

- Korea
- 30 May 2023


Mitochondria Electron Microscopy (peripheral blood mononuclear cell) 

NECA HTA-2023-33



SNP marker analysis

- Korea
- 30 May 2023

Single nucleotide polymorphisms markers analysis in allogenic hematopoietic stem cell transplantation 

NECA HTA-2023-32



## Other Guidance



## Cancer



### Bevacizumab

Bevacizumab for recurrent platinum-sensitive ovarian cancer

CADTH RC1481-000

- Canada
- 17 May 2023



### Carbon-ion radiotherapy

Carbon-ion radiotherapy

NECA HTA-2023-27

- Korea
- 17 May 2023



### Futibatinib

Futibatinib (Lytgobi®) for the treatment of locally advanced or metastatic cholangiocarcinoma

AIHTA

- Austria
- 25 May 2023



### Glofitamab

Glofitamab (Columvi®) as monotherapy for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

AIHTA


- Austria
- 25 May 2023



## Other Guidance



### Cancer



### Cardiovascular



#### Nutrition

Nutrition as prevention for improved cancer health outcomes

AHRQ

- USA
- 22 May 2023



#### AI screening ECG

Artificial Intelligence-based screening test for left ventricular systolic dysfunction using 12-lead electrocardiogram data

NECA PV-2003-4

- Korea
- 30 May 2023



#### Pirtobrutinib

Pirtobrutinib as monotherapy for the treatment of relapsed or refractory mantle cell lymphoma

AIHTA

- Austria
- 25 May 2023



#### Valve replacement

Transcatheter mitral valve-in-valve replacement

NECA HTA-2023-34

- Korea
- 30 May 2023



## Other Guidance



### Endocrine



### Eye



QCT

Quantitative Copeptin  
Test

NECA HTA-2023-23

- Korea
- 08 May 2023



IRIS

Intraocular IRIS  
Implantation

NECA HTA-2023-26

- Korea
- 08 May 2023



## Other Guidance




## Genitourinary



### Water cleansing

- Korea
- 08 May 2023


 Vagina cleaning using plasma-activated water and light emitting diode

*NECA HTA-2023-20*





## Other Guidance



## Infection



### COVID-19 RT-LAMP

- Korea
- 30 May 2023

SARS-CoV-2 [Reverse  
Transcription Loop-  
mediated Isothermal  
Amplification, RT-LAMP]

NECA HTA-2023-28



### Mycobacterium avium complex test

- Korea
- 08 May 2023

Mycobacterium avium  
complex test in  
respiratory specimens  
[Real-time PCR]

NECA HTA-2023019



### Non-TB Mycobacterium species test


- Korea
- 08 May 2023

Non-tuberculosis  
Mycobacteria species  
test using non-cultured  
specimen

NECA HTA-2023-21



## Other Guidance




## Musculoskeletal



### Extracorporeal shock wave therapy

- Austria
- 25 May 2023




Extracorporeal shock wave therapy for orthopaedic indications

AIHTA



### Plasma injection

- Korea
- 30 May 2023




Autologous leukocyte-rich platelet-rich plasma Injection for rotator cuff tendinopathy

NECA HTA-2023-29



### Prolotherapy

- Korea
- 08 May 2023



Prolotherapy of suboccipital, upper cervical and temporomandibular joint area

NECA HTA-2023-24



## Other Guidance



## Neurology



### Alternative Therapies

- Canada
- 15 May 2023

Alternative therapies to immunoglobulin for Guillain-Barré syndrome

CADTH RC1480-000



### Nerve blocks

- Korea
- 30 May 2023

Cranial nerve restoration combining repeated nerve blocks with stimulation of auditory and non-auditory nerves via the trigeminal and facial cranial nerves by hypodermic needle  
NECA HTA-2023-30



### Nerve stimulation

- Austria
- 25 May 2023

Radiofrequency denervation for chronic lumbar or cervical spine pain


AIHTA



## Other Guidance



### Pregnancy



### Skin



#### IV-Ig

- Austria
- 25 May 2023

IV Immunoglobulins in recurrent in vitro fertilisation implantation failure and/or recurrent pregnancy loss

AIHTA



#### Alternative Therapies

- Canada
- 29 May 2023

Alternative therapies to immunoglobulin for autoimmune blistering diseases

CADTH RC1483-000



#### Management of PHD

- USA
- 31 May 2023

Management of Postpartum Hypertensive Disorders of pregnancy

AHRQ



## About Us

Crystallise provides an innovative approach to identify and synthesise information, using AI to automate processes and assist our experts to produce deliverables that provide real value to clients.

Our team of researchers, medical writers and copy-editors deliver strategically-relevant and comprehensive written reports as well as visually informative summary slide decks, to suit internal business development, market access, journal publication and health technology assessment submissions.

## REVIEWS

Systematic Literature Reviews  
Global Value Dossiers  
Narrative Reviews  
Rapid Reviews  
Targeted Reviews

## HEALTH ECONOMICS

Return on Investment  
Network Meta-Analysis  
Budgetary Impact Analysis  
Cost-effectiveness Analysis

## ACTUARIAL

Risk Management  
Pricing & Reserving

## MODELLING

Mortality and Morbidity Modelling  
Synthetic Sample Generation  
Infectious Disease Modelling

[To provide feedback on the HTAngel newsletter, click here.](#)

[To unsubscribe, click here.](#)

**Registered address**

17 High Street,  
Stanford-le-Hope,  
Essex, SS17 0HD  
+44 (0)1375 517878

**Company No:** 7980921

**Data Protection Act Registration Number:** Z3363643

**Websites:**

[www.crystallise.com](http://www.crystallise.com)

[www.heoro.com](http://www.heoro.com)

[www.evidencemapper.co.uk](http://www.evidencemapper.co.uk)